Literature DB >> 26538137

Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization.

Clara Weil1, Chizoba Nwankwo2, Mira Friedman1,3, Gabriel Kenet1, Gabriel Chodick1,3, Varda Shalev1,3.   

Abstract

Hepatitis C affects an estimated 130 million people worldwide and is a major cause of chronic liver disease. This retrospective database study aims to describe the epidemiology of HCV-infected patients in Maccabi Healthcare Services, a 2-million-member health maintenance organization in Israel. HCV was identified by cross-linking diagnoses, laboratory data, and dispensed HCV treatment (1993-2013). The point-prevalence of HCV in 2012 and annual incidence of newly-diagnosed HCV during 2003-2012 (index period) were calculated. The age-adjusted prevalence of HCV was 5.19/1,000 population (n = 10,648). The highest prevalence was found among males and in patients aged 35-54 years. Two thirds of HCV-infected patients were immigrants from the former Soviet Union (FSU). HCV genotype 1 was predominant (67%). A total of 6,150 patients were newly diagnosed with HCV infection during the index period. The age-standardized rate of newly-diagnosed HCV declined from over 50/100,000 (2003) to 15/100,000 (2012). This rate was highest in males from the FSU, particularly for birth cohorts in 1950-70. The study results suggest that the reported incidence of HCV infection in Israel is declining, while prevalence is particularly high among FSU immigrants and genotype 1 is predominant. As the HCV treatment landscape evolves, these estimates can inform future studies and health technology assessments.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  HCV genotype; antiviral therapy; comorbidities; healthcare utilization; incidence; prevalence

Mesh:

Year:  2015        PMID: 26538137     DOI: 10.1002/jmv.24426

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Gender-sensitive word embeddings for healthcare.

Authors:  Shunit Agmon; Plia Gillis; Eric Horvitz; Kira Radinsky
Journal:  J Am Med Inform Assoc       Date:  2022-01-29       Impact factor: 4.497

2.  Hepatitis C Virus Nonstructural 5A Protein (HCV-NS5A) Inhibits Hepatocyte Apoptosis through the NF-κb/miR-503/bcl-2 Pathway.

Authors:  Zhengyuan Xie; Zhihua Xiao; Fenfen Wang
Journal:  Mol Cells       Date:  2017-03-27       Impact factor: 5.034

3.  Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C.

Authors:  Nitzan Avisar; Yael Heller; Clara Weil; Aviva Ben-Baruch; Shani Potesman-Yona; Ran Oren; Gabriel Chodick; Varda Shalev; Nachman Ash
Journal:  Isr J Health Policy Res       Date:  2017-09-28

Review 4.  Epidemiology and management of hepatitis C virus infections in immigrant populations.

Authors:  Nicola Coppola; Loredana Alessio; Lorenzo Onorato; Caterina Sagnelli; Margherita Macera; Evangelista Sagnelli; Mariantonietta Pisaturo
Journal:  Infect Dis Poverty       Date:  2019-03-15       Impact factor: 4.520

5.  Country versus pharmaceutical company interests for hepatitis C treatment.

Authors:  Roy Lothan; Noa Gutman; Dan Yamin
Journal:  Health Care Manag Sci       Date:  2022-08-24

Review 6.  The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Hossein Ghaderi-Zefrehi; Mohammad Gholami-Fesharaki; Heidar Sharafi; Farzin Sadeghi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-08-23       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.